Sino Biopharmaceutical Ltd stock (KYG8087W1029): Hong Kong shares react to new Phase II culmerciclib data at ASCO 2026

Sino Biopharmaceutical Ltd shares in Hong Kong traded against the backdrop of fresh Phase II data for its CDK2/4/6 inhibitor culmerciclib in resistant breast cancer, presented around the ASCO 2026 meeting and detailed in a new voluntary announcement.

Sino Biopharm shares on the Hong Kong Stock Exchange traded on 06/02/2026 in the slipstream of new clinical data for its oncology pipeline, as the company highlighted Phase II results for its oral CDK2/4/6 inhibitor culmerciclib in hormone receptor-positive, HER2-negative breast cancer at the time of the ASCO 2026 meeting, according to a voluntary announcement filed with HKEX on 06/02/2026 and related coverage from TipRanks on 06/02/2026.HKEX announcement as of 06/02/2026TipRanks as of 06/02/2026

The stock, which trades in Hong Kong under ticker 1177 in Hong Kong dollars, remained in focus among investors in the company’s home market of Hong Kong as culmerciclib advances into Phase III development for HR+/HER2- breast cancer and as the group continues to expand its innovative oncology franchise alongside its established portfolio of generic and specialty medicines in China.HKEX data as of 06/02/2026

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Sino Biopharm
• Sector/industry: Pharmaceuticals and biotechnology, with a focus on innovative and generic drugs
• Headquarters/country: Hong Kong, Hong Kong
• Core markets: Mainland China and other Asian markets
• Key revenue drivers: Branded and generic prescription medicines, oncology and hepatology therapies, and other specialty pharmaceuticals
• Home exchange/listing venue: Hong Kong Stock Exchange (1177)
• Trading currency: HKD

Sino Biopharmaceutical Ltd: core business model

Operating out of Hong Kong, Sino Biopharm focuses on discovering, developing and commercializing a broad portfolio of branded and generic prescription drugs, with oncology, liver disease and other chronic conditions forming the backbone of its revenue generation in mainland China and selected international markets.

Latest quarterly results for Sino Biopharmaceutical Ltd at a glance

For the latest reported financial period, Sino Biopharm published its full-year 2025 results on 03/20/2026, providing the most recent comprehensive snapshot of its profitability and cash generation profile, according to the company’s investor relations materials on that date.Company investor relations as of 03/20/2026

In that FY 2025 release, Sino Biopharm detailed trends in revenue from its key therapeutic franchises and highlighted continued investment into R&D, including oncology projects such as culmerciclib and other targeted cancer agents, underlining how late-stage clinical assets like the CDK2/4/6 inhibitor contribute to the group’s longer-term earnings trajectory and capital allocation decisions in Hong Kong and its main operating markets.

Conclusion

The focus on culmerciclib’s Phase II data in resistant HR+/HER2- breast cancer and the progression of the CDK2/4/6 inhibitor into Phase III underline how Sino Biopharmaceutical Ltd is seeking to reinforce its oncology pipeline alongside its established drug portfolio in mainland China and wider Asia.

Investors in Hong Kong and beyond will likely monitor upcoming clinical milestones and any subsequent updates to the company’s financial guidance and capital deployment, particularly as late-stage R&D outcomes feed into the earnings picture outlined in the FY 2025 results.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.